AstraZeneca ULTOMIRIS: zero relapses in neuromyelitis optica spectrum disorder

Results from CHAMPION-NMOSD trial demonstrated ULTOMIRIS reduced the risk of relapse in AQP4 Ab+ NMOSD by 98.6% compared to placebo

ULTOMIRIS also showed a lower proportion of patients experiencing clinically important worsening in Hauser Ambulatory Index score, a measure of patient mobility

Strong results across several subgroup analyses add to growing body of evidence supporting C5 inhibition in NMOSD

https://finance.yahoo.com/news/ultomiris-ravulizumab-cwvz-showed-zero-110000969.html